Ixekizumab: an alternative for HIV-positive psoriasis patients

Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present...

Full description

Saved in:
Bibliographic Details
Published in:AIDS research and therapy 2024-11, Vol.21 (1), p.87-3
Main Authors: Liu, Fanghua, Liu, Zhou, Yang, Rongming, Huang, Dandan, Han, Yongzhi
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Adult
AIDS
Antibodies, Monoclonal, Humanized - therapeutic use
Biological products
Biopharmaceuticals
Care and treatment
Case Report
Dermatologic Agents - therapeutic use
Development and progression
Diagnosis
Drug therapy
Erythema
Health aspects
HIV
HIV (Viruses)
HIV infection
HIV Infections - complications
HIV Infections - drug therapy
HIV patients
Human immunodeficiency virus
Humans
Infection
Infections
Inflammatory diseases
Interleukin 17
Interleukin-17 - antagonists & inhibitors
Ixekizumab
Kidney diseases
Lymphocytes
Male
Middle Aged
Monoclonal antibodies
Pathogenesis
Patient outcomes
Patients
Prevention
Psoriasis
Psoriasis - complications
Psoriasis - drug therapy
Psoriatic arthritis
Quality of life
Recurrent infection
Risk factors
Skin
Skin diseases
Skin lesions
Systematic review
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present a case of the efficacy and safety of Ixekizumab, an interleukin 17 inhibitor, in the treatment of psoriasis patients living with HIV (PPLHIV).
ISSN:1742-6405
1742-6405
DOI:10.1186/s12981-024-00675-8